ABT - Abbott Laboratories

ABT

$91.74 0.98 (-1.06%)

After Hours: $91.74 +0.00 (+0.00%)

Last updated: Apr 22, 2026 21:34

52-Week Range

$91.74

$91.59 $91.74 $139.06

Fundamentals Overview

Abbott Laboratories is near the low of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 25.5 P/B 3.07 P/S 3.53

Intrinsic value (DCF)

+44.1% upside vs price

Profitability

Net margin 13.9%

Risk (Beta)

0.78 — lower vol

Earnings & growth

EPS $3.59 Rev -2.6% Profit -39.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 55% confidence Risk: Lower Volatility — Beta 0.78. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +44.1% upside vs price · Sentiment improving (1 upgrade)

Pressures (Sell):

3M vs S&P 500: -29.3% · 3M vs Healthcare sector: -18.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$159.42B

P/E (TTM)

25.54

EPS (TTM)

$3.59

Dividend Yield

1.37%

52-Week Range

$91.59 - $139.06

Volume vs Avg

N/A

Beta

0.78

About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecologi...

Sector: Healthcare

Headquarters: US

Employees: 114,000

IPO Date: Mar 1980

Website: www.abbott.com

Beta: 0.78 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 11, Outperform: 11, Overweight: 8.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $132.19; current price is $91.74. That’s a +44.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	25.54
DCF value (model)	$132.19 (44.1% upside)
PEG (TTM)	N/A
P/B (TTM)	3.07
P/S (TTM)	3.53
P/FCF (TTM)	21.56
Liquidity & enterprise
Current Ratio (TTM)	1.58
Quick Ratio (TTM)	1.18
Cash Ratio (TTM)	0.52
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	13.91%
Gross margin (TTM)	56.38%
Operating margin (TTM)	18.17%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ABT.

Analyst Sentiment at a Glance

C Sentiment Improving

Buy 11Outperform 11Overweight 8

1 upgrade, 0 downgrades

Price Target Consensus

Current $91.74

Median $125.00

Consensus $128.71

Low consensus $92.00

High consensus $152.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
BTIG	maintain	Buy	Buy	2026-04-17
Piper Sandler	maintain	Overweight	Overweight	2026-04-17
B of A Securities	maintain	Buy	Buy	2026-04-17
Oppenheimer	maintain	Outperform	Outperform	2026-04-17
Evercore ISI Group	maintain	Outperform	Outperform	2026-04-17
Stifel	maintain	Buy	Buy	2026-04-17
RBC Capital	maintain	Outperform	Outperform	2026-04-17
Benchmark	maintain	Buy	Buy	2026-04-17
Goldman Sachs	maintain	Buy	Buy	2026-04-09
Barclays	maintain	Overweight	Overweight	2026-04-08
Evercore ISI Group	maintain	Outperform	Outperform	2026-04-06
BTIG	maintain	Buy	Buy	2026-03-31
Piper Sandler	maintain	Overweight	Overweight	2026-03-26
Citigroup	maintain	Buy	Buy	2026-03-11
Barclays	maintain	Overweight	Overweight	2026-02-02
Freedom Broker	upgrade	Hold	Buy	2026-01-29
Citigroup	maintain	Buy	Buy	2026-01-23
Bernstein	maintain	Outperform	Outperform	2026-01-23
Piper Sandler	maintain	Overweight	Overweight	2026-01-23
Evercore ISI Group	maintain	Outperform	Outperform	2026-01-23
RBC Capital	maintain	Outperform	Outperform	2026-01-23
BTIG	maintain	Buy	Buy	2026-01-23
Oppenheimer	maintain	Outperform	Outperform	2026-01-23
Bernstein	maintain	Outperform	Outperform	2026-01-09
Barclays	maintain	Overweight	Overweight	2026-01-05
BTIG	maintain	Buy	Buy	2025-11-20
Barclays	maintain	Overweight	Overweight	2025-10-17
Evercore ISI Group	maintain	Outperform	Outperform	2025-10-16
RBC Capital	maintain	Outperform	Outperform	2025-10-16
Wells Fargo	maintain	Overweight	Overweight	2025-10-16